Altered Fate

After spooking investors by disclosing a clinical delay in its S-1, Fate Therapeutics Inc. (NASDAQ:FATE) decided to accept a drastically reduced price from what it has been seeking in exchange for a public listing and enough cash to turn over some important cards.